AVEO Pharmaceuticals, Inc. (AVEO) Financial Analysis & Valuation | Quarter Chart
AVEO Pharmaceuticals, Inc. (AVEO)
AVEOPrice: $15
Fair Value: 🔒
🔒score
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of ren... more
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing m... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Michael P. Bailey |
| IPO Date | 2010-03-12 | CAGR | 0.09% |
| Employees | 114 | Website | www.aveooncology.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AVEO chart loading...
Fundamentals
Technicals
| Enterprise Value | $246.19M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 11.24 |
| P/CF Ratio | -9.01 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 255.97% | Gross Margin | 0.88% |
| Operating Margin | -1.27% | Profit Margin | -1.57% |
| ROE | -1.51% | ROA | -0.58% |
| ROCE | -0.57% | Current Ratio | 5.59 |
| Quick Ratio | 5.5 | Cash Ratio | 3.77 |
| Debt/Equity | 0 | Interest Coverage | 12.25 |
| Altman Z Score | — | Piotroski Score | — |